Xilio Therapeutics (NASDAQ:XLO) Posts Quarterly Earnings Results, Beats Expectations By $2.49 EPS

Xilio Therapeutics (NASDAQ:XLO) issued its quarterly earnings data on Monday. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.68) by $2.49, FiscalAI reports. The company had revenue of $13.69 million during the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%.

Xilio Therapeutics Stock Performance

XLO opened at $7.86 on Monday. Xilio Therapeutics has a 52-week low of $6.47 and a 52-week high of $16.52. The firm has a market capitalization of $41.27 million, a PE ratio of -0.86 and a beta of -0.05. The business’s 50-day simple moving average is $8.05 and its 200 day simple moving average is $9.62.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Institutional Investors Weigh In On Xilio Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in XLO. Bain Capital Life Sciences Investors LLC grew its stake in shares of Xilio Therapeutics by 61.4% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock valued at $4,720,000 after buying an additional 2,805,869 shares in the last quarter. Ghisallo Capital Management LLC bought a new position in shares of Xilio Therapeutics in the 4th quarter valued at about $713,000. Renaissance Technologies LLC grew its position in shares of Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after acquiring an additional 139,716 shares during the period. Squarepoint Ops LLC increased its stake in shares of Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares during the period. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.